Your going to see a lot of new people here because of PSC. Put it this way... Last time PSC announced a new stock on Twitter before releasing a newsletter, the stock ran up over 60% (ZENG)

The trick is to get in before they announce it via Newsletter. So IF they send out a newsletter tonight (after close), the stock will GAP up tomorrow morning. But then you HAVE to take profits. Because it will fall faster than it rose. Of course this is all IMO. We can't predict what PSC will do.

GL

I'm in and will be staying in for a while.

At midday, BRYN our #1 gold play is trading at $0.51 up 16% on healthy volume as the shorts continue to feel the pain.


BRYN was out this morning with an announcement that they have:

"entered into a confidentiality agreement with Trueclaim Exploration Inc., a publicly listed TSX company, which carries on business as a mineral exploration and mining company (http://www.Trueclaim.ca )." and " This is the first step leading to what the parties expect to be the execution of an LOI in respect to a Joint Venture Agreement in regards to the Montauban Property in Quebec. Bryn Resources recently entered into an LOI with Dominic Gingras to purchase of a majority interest in this property."

Here's a little D.D for our members on Trueclaim Exploration Inc:

Trueclaim is building a growing list of Canadian properties for mineral exploration and development.
A mineral exploration company with a growing portfolio of gold properties.
Properties located in prospective areas with long histories of mining
Properties located in mine-friendly Ontario.
The directors and management team bring to the company decades of practical experience in mineral exploration, development, mining and processing.
Listed on the TSX-Venture exchange (Symbol: TRM)
Management at Trueclaim is stacked with seasoned veterans from the mining industry.

Trueclaim has 2 properties on the go right now:

Scadding: http://www.trueclaim.ca/scadding-property.php

Sandeb: http://www.trueclaim.ca/sandeb-property.php

This is very exciting news for shareholders of both companies as the combined efforts of BRYN and TRM will be sure to increase shareholder value in the near term



The short squeeze has begun, we are noticing more and more market makers known to be short getting very nervous as their capital is depleted daily.

The fun is just starting, $.50 was crossed today, breaking some minor upside resistance.
A near term double from here is in our sights

This is not uncommon. About one month ago I remember people complaining about their stock splits not showing up until a week after everyone else's. So I'm sure they same may happen with dividends I would just call your Broker and ask to verify. GL

So do I. Gotta love free trades...

No. But if the company ever gets listed or bought out you can. When did you hold your position in VIVK (date you purchased)?

PSC Tweet...


MEXP is rocketing higher. PSC has seen the treasure the deal is real.

Post on Twitter from PSC...

(BRYN)is up15%and(ZENG)is up8% both these companies have done well for our follwers and have more to bring GET IN

I really wish I had some free cash. I was in IDOI this morning so I can add these cheaps.

I'm alerting this to others...we shall see what happens.

Today, The Preacher has a BRAND NEW BIOTECH IDEA for you to look at!

Presenting.....

Vivakor, Inc. - Trading Symbol: VIVK

Before we share with you all the reasons why we like VIVK as a
company, we first want you pay close attention to a few of the
technicals. We believe the chart could be signaling higher prices for
VIVK.

For example...
1) After an impressive move higher in the middle of October, the stock
has given way to profit-taking on contracting downside volume. This
suggests the selling may have exhausted itself and the stock could be
ready for a bounce higher.

2) The MACD`s downside momentum may be losing steam suggesting a rally
may be on the way.

3) The stock is currently at (or very near) the level it was at before
its last major move higher. Could it be poised to retest its recent
high

4) The stochastics is DEEPLY OVERSOLD indicating that the stock may
have fallen too far and too fast...and that buying interest may return
very soon.


If those technical reasons are the fuel for a rally, here is the
catalyst: Last night VIVK announced a new acquisition strategy which
could significantly add to its bottom-line. Read the whole news
release for yourself by VIVK news release

So what exactly does this Biotech company do...you ask

VIVK divides its research efforts into FOUR primary areas of medical
and biotechnological development. These divisions are (1) Molecular
Medicine (2) Electro-Optics (3) Biological Handling (4) Natural and
Formulary Products.

The Preacher thinks each of these divisions may offer STRONG GROWTH
POTENTIAL. Here is a sample of some of the more promising products
and technologies that VIVK is working on.

· Vivathermic Vials---VIVK estimates that it may capture up to 1.5% of
the $1.9 billion market for laboratory bioconsumables by 2011 and
industry leading distributors anticipate a 3% annual growth in
cryovial sales segment. VIVK has developed specialized cryovials that
accommodate an improved method of cryopreservation of cells, blood,
and other bio-materials. The company recently announced distribution
of its VivaThermic products to the rapidly growing biotech/biopharma
industries in India through its agreement with Pro Lab Marketing Pvt.
Ltd.

Management believes that its sales could see a sizeable increase for
this product line as the market realizes the benefits over competitive
products.

For example, VivaThermic Vials will thaw the sample 3 times faster
than market leading vials. The VivaThermic Vials also have a unique
2-in-1 design. This dual functionality is expected to improve
customer production efficiency and reduce time and material costs by
eliminating the need to transfer samples between vials and
microcentrifuges.

· VivaBlend--VIVK`s PROPRIETARY balanced blend of more than 18
different sources of phytochemical extracts from antioxidant rich
bioactive fruits and vegetables tested by the USDA that can be added
to many consumer foods, drinks and nutraceuticals as a convenient
daily source of important antioxidants and other critical bioactive
phytochemicals.

· VivaSight--VIVK has developed a device that may modernize screening
of pre-verbal and pre-literate children for ocular disorders. Already
a $50 million a year market, this type of screening is increasingly
required by state governments prior to enrollment in the public school
system.


The company believes this technology (device, software and
accessories) could modernize child vision screening. With
anticipation of legislatively mandated pediatric vision screening,
demand for these products could skyrocket.

The Company is anticipating launching its product next summer!

· Vivaslices-- This technology is a software upgrade to older MRI
units that allow the unit to achieve HIGHER RESOLUTION using a
patented algorithm. The underlying algorithm may be useful in the
determination of blood flow velocity measures in imaged tissues. Such
information would be valuable in accessing areas of blood flow
constriction from plaques or other hematologic deposits.

Management believes this may help physicians better diagnose, predict
and assess stroke and related diseases involving blood flow
obstruction in this $300 million market.

..And check this out!

Just last month the Company announced it has completed an exclusive
distribution agreement with consumer product specialist, Regeneca
International, Inc. for one of its proprietary, cutting-edge
nutraceutical formulations.

This purchase represents another SUBSTANTIAL REVENUE STREAM for VIVK`s
emerging nutraceutical division AND resulted in an immediate purchase
for 25,000 units of the product.

VIVK`s CEO Tannin Fuja explained, "We are very excited for the
possibilities of Vivakor`s line of nutraceutical products. Worldwide
demand for nutraceutical products is expected to exceed $15 billion
and Vivakor plans on being a substantial player in that market." To
read the complete article Click Here.

We encourage members to take a very close look at VIVK as The Preacher
sees significant upside potential both near-term and longer-term.

Remember to always use the appropriate stop losses, trailing stop
losses and anything else you can think of in order to protect your
investment should you decide to trade in this stock!

Remember - "Knowledge is Power" and as always here at
StockPreacher.com, we strive to give you all the best information
available!


Best Regards,StockPreacher

info@stockpreacher.com

Vivakor Inc. (VIVK.ob) Bounce Alert

Vivakor Inc. (VIVK.ob) has now entered our radar and being placed on our
prestigious bounce alert watch!!!

After its initial run up on strong volume in late October, the stock has
settled into a base. Volume in recent days has slowed as we see support at
this level; the price stability has allowed for some of the technical
indicators to improve. The shares seem poised for a reversal to the upside
after coming back towards their initial breakout point. The recent share
gains have allowed toxic share positions to find their way out of the stock
and initialize a clean slate for the next big move!!!

VIVK has been releasing BIG NEWS these past weeks creating huge buzz in
the investing world. Their most recent news released Tuesday announced the
procedure for how shareholders of record on December 1, 2009 will receive
the dividend of shares of common stock of HealthAmerica, Inc. Each Vivakor
shareholder will be entitled to receive one share of HealthAmeria common
stock for each share of Vivakor common stock beneficially owned on December
1, 2009. This news has pleased the Companys shareholders and has only
improved their situation as a growing company going into the future!!!

About Vivakor, Inc. (VIVK.ob)

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary
research
that develops and acquires products in the fields of molecular medicine,
electro-optics,
biological handling and natural and formulary compounds, that extend or
improve
life. The R&D Core at Vivakor (the idea hub) innovates, develops and
validates biomedical
devices and biotechnologies. Commercialization of Vivakor technologies is
accomplished
through partnerships with manufacturers and niche-industry marketing and
distribution
leaders. Vivakor generates revenues through the licensing or sale of its
technologies.
Vivakor is preparing a portfolio of intellectual properties and
subsidiaries. The
subsidiaries will focus on the commercialization of technologies
developed by Vivakor.

More information can be found about Vivakor (VIVK) at
www.vivakor.com

Best Regards,

FHPS Staff

“Stock Pick” Update



(OTCBB: VIVK)

News Released Today!

Vivakor Announces Mechanics of Dividend Distribution

Yesterday, Vivakor issued another press release to further explain how it will issue a stock dividend to shareholders of record December 1. We note that Vivakor has several operating entities, and it is very possible that additional stock dividends will be awarded in the future. Better yet, The Green Baron Report believes the current drop in price to about .24 per share represents a fantastic entry point, and we could see a 100 to 200% move up over the next 30 to 45 days. Here is your early Christmas present!

Dec 8, 2009 11:11:00 AM EST
CORALVILLE, Iowa, Dec. 8 (PRNewswire-FirstCall) - Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the mechanics for how shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor's Board of Directors. HealthAmerica is a private Nevada corporation of which Vivakor owned approximately 84% of the outstanding common shares on the record date. The distribution date will be December 9, 2009, and will be conducted as an "upon surrender" distribution. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. The shares of Health America being distributed shall be recorded in the name of each Vivakor shareholder of record on December 1, 2009 as a journal entry with the transfer agent, Integrity Stock Transfer, located in Las Vegas, Nevada. Any shareholder of Vivakor as of the record date, December 1, 2009, may request a certificate directly from the transfer agent, or may simply request a confirmation that a journal entry of the shares with the transfer agent. No other action is required by the Vivakor shareholders to obtain their shares.

About Vivakor, Inc.

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor atwww.vivakor.com.

About HealthAmerica, Inc.

HealthAmerica is developing a patented, FDA 510(k) cleared, technology (VIVASlices(TM)) that is expected to enhance the resolution of images resulting from MRI. The underlying algorithm may also be useful in determining blood flow velocity measures in imaged tissues, which would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits. This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.

At the end of 2000, there were approximately 9,500 MRI (magnetic resonance imaging) systems installed worldwide. While changes in medical reimbursements have slowed the sale of new machines, there is an increased demand for improved efficiency (i.e. accelerated patient throughput) from current systems. Additionally, intense competition between various medical facilities and the rapid distribution of new advances in imaging (such as MR angiographies, which allow evaluation of blood vessels without any invasive procedure) puts additional pressure on MRI because increased image quality requires additional time. Thus there is a huge need for an application like VIVASlices that can improve both throughput and image quality.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's and HealthAmerica's products and markets. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact:

Vivakor, Inc.
Matt Nicosia
1-319-625-2172
mnicosia@vivakor.com

Zecco and TD but Zecco is where the trade took place.

It was in my account this morning as HEAAME.


The distribution date will be December 9, 2009, and will be conducted as an "upon surrender" distribution. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. The shares of Health America being distributed shall be recorded in the name of each Vivakor shareholder of record on December 1, 2009 as a journal entry with the transfer agent, Integrity Stock Transfer, located in Las Vegas, Nevada. Any shareholder of Vivakor as of the record date, December 1, 2009, may request a certificate directly from the transfer agent, or may simply request a confirmation that a journal entry of the shares with the transfer agent. No other action is required by the Vivakor shareholders to obtain their shares.

Over all I take profits fairly quickly. However, what I have noticed; if your caught holding the bag after a P & D, your better off holding until the next big PR or P & D comes. Prime example, I was in VIVK and went away for 2 days. When I came back I was down 60%. I decided to hold until the next PR. Today exactly that happened.

Righttt...I'm up 100% just from a few days ago.

Huge volume increase

LOL. I received my "dividend" today. It's nice to have shares in our account that show $0.00...

Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products

CORALVILLE, Iowa, Dec. 10 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced that it has entered into an exclusive, $5 million license agreement with consumer product specialist, Regeneca International, Inc. (http://www.regeneca.com/). The agreement exclusively licenses to Regeneca distribution rights to a new cutting-edge nutraceutical formulation developed by Vivakor and provides for the development of future formulations by Vivakor for Regeneca. Under the terms of the agreement, Regeneca shall be the exclusive worldwide direct-to-consumer distributor for the current formulation as well as any future nutraceutical formulations offered to Regeneca by Vivakor. Regeneca has committed to purchase from Vivakor a minimum of $5 million in product over the next three years and Vivakor will receive a 15% ownership interest in Regeneca's outstanding common stock and will be the exclusive supplier of the licensed product to Regeneca

The companies entered into this agreement following a successful test marketing of one of Vivakor's formulations, which was followed by an initial Regeneca order of over $100,000 of product. This purchase will represent another substantial revenue stream for Vivakor's emerging nutraceutical division. Vivakor CEO Tannin Fuja expressed his enthusiasm for the transaction, "We are extremely enthusiastic about the significant growth potential of Vivakor's growing line of nutraceutical products. Worldwide demand for nutraceutical products is expected to exceed $15 billion and Vivakor plans on being a substantial player in that market."

Dr. Fuja continued, "We are particularly pleased to include in the formulation the powerful, marquis super-antioxidant yum berry (yang-mei in Chinese), also known as red bayberry, which is harvested from one hundred-year-old trees, and the flavonoid-rich concord grape, which has been shown to contain potent antioxidants that may protect against oxidative stress and reduce the risk of free radical damage and chronic diseases."

Regeneca's President, Larry Walter gave his thoughts on the purchase, "From our standpoint, this transaction makes a great deal of sense. The pilot program demonstrated great promise for Vivakor's products from both a commercial and personal health perspective. Regeneca is certain to be able to develop a strong niche in the nutraceutical market with this terrific product and those to follow from this agreement."

About Vivakor, Inc

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds including nutraceutical products, that extend or improve life. More information can be found about Vivakor at http://www.vivakor.com/

About Regeneca International, Inc

Regeneca(TM) International, Inc. was formed to create and commercialize products that help consumers improve their health, battle the signs and symptoms of aging and to assist in "regenerating their lives" through its family of natural, organic and phytochemical infused products. The corporate creed is to regenerate the human genetic environment through ecology-centric science. All Regeneca products must fit the highest standard of conservation and reduced carbon footprint. The products must also work to preserve and promote the user's health at the most elemental level of life; the genetic level. The Company's products and philosophy are designed to reconnect the consumer to the Earth's source of healing properties, but with a symbiotic approach. This is the company's "Whole Earth, Whole Body Approach to Health."

Already a market presence in the multibillion dollar nutraceutical market, Regeneca's proprietary, direct-to-consumer marketing strategy will push the company to the forefront of emerging consumer product companies. Regeneca anticipates at least a 500% increase in sales in 2010 and a similar increase in 2011

More information can be found about Regeneca International, Inc. at http://www.regeneca.com/

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's nutraceutical products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes

Contact: Vivakor Investor Relations c/o IME Advisors (888) 648-8485

DATASOURCE: Vivakor, Inc

CONTACT: Vivakor Investor Relations, c/o IME Advisors, +888-648-8485

Web Site: http://www.vivakor.com/

BRYN, THE STARS ARE ALIGNED, The shorts are going to get killed when we get the next big news.

BRYN closed up 15.8% at .44. We are up 1417 % on BRYN since our initial alert at .029.



We know for sure that there are shorts in this stock. PSC spoke with BRYN today and they expect to be in a position to release more news on their short fighting effort at the close on Thursday.

BRYN is serious about fighting the shorts. If I was short BRYN, I would be concerned.

The last PR from the company gives us a taste of what to expect.

Bryn Resources Inc. Announces Signing of the a Rescission Agreement with DRLLC

2009-12-07 21:51 ET - News Release

TORONTO, Dec. 7 /PRNewswire-FirstCall/ - Bryn Resources Inc (PINKSHEETS: BRYN) (PINKSHEETS: BRYN) is pleased to announce the signing of a Rescission agreement between itself and DRLLC in respect of the DRLLC claims in Nevada which were the subject matter of an agreement entered into between Bryn Resources and DRLLC dated December 29th 2008. Bryn Resources will seek approval from its Board for the cancellation of the shares issued in furtherance of the original agreement to be effective on a date yet to be determined but in any event prior to January 15th 2010 when the shares would have otherwise become free trading. Bryn Resources will keep its shareholder up to date by announcing the date upon which the board will effectively cancel the shares.

Bryn Resources

CONTACT: Bryn Resources Inc, Paul Diana, (416) 347-6548

Please remember to do your due diligence on BRYN

Vivakor Announces New Acquisition Strategy

CORALVILLE, Iowa, Dec. 9 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced its acquisition strategy for the next 12 months. Executive Chairman, Matt Nicosia detailed the key points of the strategy: "We are currently looking at specific transactions involving companies with technologies that fit neatly into our 'hub and spoke' model, as well as companies which have existing commercialization channels that serve our own commercialization strategies for products developed internally." When asked about the timing of any future acquisitions, Mr. Nicosia responded, "We are looking at opportunities all the time. When one appears which fits within our stated strategy, we'll move forward with all due course." Future announcements of any acquisitions will be made as material events occur

About Vivakor, Inc

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at http://www.vivakor.com/

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes

Contact: Vivakor Investor Relations c/o IME Advisors (888) 648-8485

DATASOURCE: Vivakor, Inc

CONTACT: Vivakor Investor Relations c/o IME Advisors, +888-648-8485

Web Site: http://www.vivakor.com/

LOL, yes I did forget a 0 didn't I? That's 1,000,000

1,025,00 buy went through Form T 4 minutes after close

..."Be Greedy When Others Are Fearful” - Warren Buffett

PSC from twitter


BRYN is up 13 percent. Gold is up again today. When the shorts cover on BRYN we are headed to $1.00

XTREMEPICKS HAS JUST LEARNED THAT A MARKET MAKER IN EUROPE MAY BE STUCK WITH A LARGE SHORT POSITION IN BRYN - POSSIBLY WELL INTO THE MILLIONS OF SHARES !!!

This is XTREME news, we are setting up for ANOTHER monster short squeeze like we witnesses Monday.

For the benefit of our newer members here's the definition of a short squeeze according to Investopedia




Short Squeeze


What Does Short Squeeze Mean?
A situation in which a lack of supply and an excess demand for a traded stock forces the price upward.

Investopedia explains Short Squeeze
Short squeezes occur more often in smaller cap stocks with small floats.

If a stock starts to rise rapidly, the trend may continue to escalate because the short sellers will likely want out. For example, say a stock rises 15% in one day, those with short positions may be forced to liquidate and cover their position by purchasing the stock. If enough short sellers buy back the stock, the price is pushed even higher.



We know there is a lack of supply: 80 million shares will be canceled.

Excess demand is happening daily, look how the bids are stacking up!

BRYN is up over 13% already today and we know management has the short sellers in their sights.

"Management is committed to building value. Shareholders can expect news on drill results on our Cayenne JV, a new JV with a Canadian mining company listed on the CNSX, and the closing of our funding.Beyond the share reduction, Bryn Resources is also considering a dual listing in Canada as a further way to combat shorts. The share reduction and the dual listing plus the anticipated results should force market makers who short the stock to cover."


As we've said before :
BRYN IS THE REAL DEAL, AND AT $0.43 STILL A STEAL !!!!

Nice little pop with the news.

What do you think we will see tomorrow?

Current Buys 53,343,312 Sells 59,105,565

Buys coming through now

Now is a good time to get in for a nice ride imo...


BRYN – THIS PR IS THE START OF A SHORT ATTACK – Expect follow through from the company this week
BRYN is at .40 this morning on strong volume. The company has taken steps to battle the shorts and we should see follow through from the PR today.



We expect to see other short battling tactics from the company. In our last conference call, BRYN told us they are looking at getting a dual Canada-US listing and a possible 10 percent dividend. This is on top of more large asset acquisitions.

THEY HAVE OFFICIALLY CANCELLED 80 MILLION SHARES.

This PR signals the start of something big.

Bryn Resources Inc. Announces Signing of the a Rescission Agreement with DRLLC

2009-12-07 21:51 ET - News Release

TORONTO, Dec. 7 /PRNewswire-FirstCall/ - Bryn Resources Inc (PINKSHEETS: BRYN) (PINKSHEETS: BRYN) is pleased to announce the signing of a Rescission agreement between itself and DRLLC in respect of the DRLLC claims in Nevada which were the subject matter of an agreement entered into between Bryn Resources and DRLLC dated December 29th 2008. Bryn Resources will seek approval from its Board for the cancellation of the shares issued in furtherance of the original agreement to be effective on a date yet to be determined but in any event prior to January 15th 2010 when the shares would have otherwise become free trading. Bryn Resources will keep its shareholder up to date by announcing the date upon which the board will effectively cancel the shares.

Bryn Resources

CONTACT: Bryn Resources Inc, Paul Diana,
(416) 347-6548

Please remember to do your due diligence on BRYN.

What's up with the sells for 120 & 175? $0.06 and $0.087

I got in late Friday with PSC stock Twitter post. The volume was 2 much to ignore. Sold today in the AM for a 47% profit. I know a lot of ppl that got in on Friday.

I agree

Vivakor Confirms Record Date of Stock Dividend
Date : 12/04/2009 @ 2:09PM
Source : PR Newswire
Stock : (VIVK)
Quote : 0.22 -0.02 (-8.33%) @ 1:51PM





Vivakor Confirms Record Date of Stock Dividend

CORALVILLE, Iowa, Dec. 4 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today confirmed that its shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor's Board of Directors. HealthAmerica is a private Nevada corporation of which Vivakor owned approximately 84% of the outstanding common shares on the record date. The distribution date is still expected to be December 9, 2009. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

About Vivakor, Inc.

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at http://www.vivakor.com/.

About HealthAmerica, Inc.

HealthAmerica is developing a patented, FDA 510(k) cleared, technology (VIVASlices(TM) that is expected to enhance the resolution of images resulting from MRI. The underlying algorithm may also be useful in determining blood flow velocity measures in imaged tissues, which would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits. This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.

At the end of 2000, there were approximately 9,500 MRI (magnetic resonance imaging) systems installed worldwide. While changes in medical reimbursements have slowed the sale of new machines, there is an increased demand for improved efficiency (i.e. accelerated patient throughput) from current systems. Additionally, intense competition between various medical facilities and the rapid distribution of new advances in imaging (such as MR angiographies, which allow evaluation of blood vessels without any invasive procedure) puts additional pressure on MRI because increased image quality requires additional time. Thus there is a huge need for an application like VIVASlices that can improve both throughput and image quality.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's and HealthAmerica's products and markets. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact: Vivakor, Inc.

Matt Nicosia, 319-625-2172

DATASOURCE: Vivakor, Inc.

CONTACT: Matt Nicosia, Vivakor, Inc., +1-319-625-2172,

Web Site: http://www.vivakor.com/

Yea, that was odd. I follow all the pumped stocks and ride the surges. When these stocks get pumped they bring new volume records and sometimes PPS. The question is always how long will it last. Sometimes it works for days, while other times it works just for a few hours (really depends on when the promoter sell their shares if they have some). If substantial news comes out this stock will shot up fast, but then come back down. Unless, "they" start selling their shares, then it's pretty much game over for a while.

IMO

Take it for what it's worth...

PANGENEX (PGCX)
MAJOR NEWS ANNOUNCEMENT



Xplosive Stocks has learned that PanGenex Corporation (PGCX) will be releasing and announcing MAJOR Breaking News tomorrow. News of this magnitude should make the stock XPLODE to well over $1.

Someone just unloaded 3,000,000 shares.